An app that lets you walk into a GP appointment with dates, patterns and questions can be genuinely useful during menopause. The problem is that the market now mixes those practical tools with products that push urine testing, wearables, subscriptions and advice that does not meet evidence standards. For UK women, the question is not whether apps work in principle, but which ones are built as care tools and which ones are built as sales funnels.
What menopause apps do well
The strongest case for apps is straightforward: they help people recognise what is happening to their own bodies. Some tools focus on psychosocial support, some on biometric tracking, some on simple period and symptom logging, and some offer educational content with tailored lifestyle advice based on what users enter. UK qualitative research shows why that matters in practice, because users often say these apps make them feel more informed, more confident and better able to explain symptoms to healthcare professionals.
A 2015 North American Menopause Society editorial described a menopausal symptom-management app as a clinical decision-support tool.
Where the evidence gets thin
The commercial market is much broader than that. The current app landscape is highly heterogeneous, and the more aggressive end of it adds proprietary at-home urine testing, wearables or AI analysis, then steers users toward interventions that are not approved by the FDA or Health Canada.
The evidence base does not justify treating all of these apps as equivalent. A 2019 systematic review found medical professional involvement in only 27% of reviewed menopause apps and evidence-based information in just under 23% of them. A 2024 systematic scoping review located 1,773 records on menopause eHealth tools but only 28 studies met inclusion criteria, and it concluded that most tools were weak on readability and on presenting balanced information.
User enthusiasm can also obscure those gaps. In a 2023 study of 18 menopause apps, 72% of reviews were positive, with users describing empowerment, self-reflection and greater confidence when talking to clinicians. That is useful, but it does not prove clinical quality. A German study published in 2025 raised continuing concerns about the accuracy of health information and the need for ongoing validation.
Privacy is another fault line. A 2023 scoping review of 14 menopause apps available on Google Play in the European Union found that most were miscategorised relative to their features and lacked adequate privacy and security safeguards. These apps collect detailed symptom histories, mood data, sleep patterns and possibly cycle information.
Why this matters in the UK
The UK policy backdrop explains why these apps are attracting so much attention. A GOV.UK literature review published in 2025 found menopause normally affects women between 45 and 55, with average onset in the UK at 51. The government’s March 2024 progress report framed menopause support as part of retaining older women in the workforce.
The economic stakes are already visible. A 2024 NHS Confederation estimate put the number of women unemployed because menopause symptoms pushed them out of work at 60,000, with an annual economic impact of GBP 1.5 billion.
UCLH and UCL launched MENO.pause on 23 July 2025 as a digital decision aid for menopause symptoms. It uses current NICE, British Menopause Society and British Gynaecological Cancer Society guidance, was supported by patient groups and menopause organisations, and was funded by North Central London Cancer Alliance, UCLH Charity, BGCS and an unrestricted grant from GSK. Its stated purpose is to help clinicians give evidence-based treatment, reduce unnecessary tests and hospital visits, and support complex cases including cancer-related early menopause.
NICE updated guideline NG23 on menopause identification and management in November 2024.
How to check an app before you pay
Use the app for logging, organising and support first. Treat diagnosis claims, bundled tests and supplement pitches as warning signs. The quickest way to separate a clinically grounded tool from a commercial one is to ask what it is actually doing with your data and what it wants you to buy next.
- Check whether clinicians are named as contributors, advisers or reviewers, and whether the app cites NICE NG23, British Menopause Society guidance or another recognised clinical framework.
- Look at the core function. A tracker, an appointment-prep tool or a support forum is one thing. An app that pushes proprietary urine tests, wearable add-ons or AI-driven treatment claims is moving into a very different category.
- Read the privacy terms before entering symptoms. The 2023 EU app review found privacy and security gaps in many apps, so you should know exactly what is collected, shared, retained and sold.
- Look for balanced information and plain language. The 2024 scoping review found readability and balance were recurring weaknesses.
- Check whether the app updates its content and references. A menopause app that never names its evidence date is asking you to trust a moving target.